Cannabis Science, Inc. a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to release new updated photos from the 3rd cancer patient self-administering cannabis extracts.
This patient has severe squamous cell carcinoma on their head that was resistant to chemo and radiation therapy, which left the patient with large tumor masses on their head. With these new photo updates you can see the drastic change in appearance of the tumors and how the topical cannabis extract is killing them.
Cannabis Science has been working very closely with this patient and is continuing to see vast improvement to his treatment resistant squamous cell carcinoma. Prior to using cannabis-based extracts this patient had received radiation and chemotherapy for his condition. This patient notices a huge difference between the treatments and had stated, “While on radiation treatments, each day was stressful and after each treatment I felt horrible as if my entire body was dying organ by organ. While using the Oil, I have noticed that my overall health seems much better. I sleep the recommended hours, unlike the insomnia I suffered while on radiation, and unlike the radiation that caused the restless sleep and nightmares, on the Oil I sleep like a baby.” The patient also mentioned that while showering they would see bits and pieces of the tumor falling off with the water as he was cleaning his head. This patient is very pleased with the results of the topical cannabis extract so far and said he enjoyed absolutely nothing about radiation and felt constantly sick and just overall unhealthy, but with using the oil he said, “I feel myself being restored, not tortured.”
Initially, when the patient began the self- administration of topically applied cannabis extract, the tumor was a solid mass (Figure 1). Subsequently, the extract killed some of the mass and a “cavern” was formed, (Figure 2), followed by the “roof of the cavern” collapsing. The latest photo (Figure 3) shows that the remaining “cavern wall” after pieces progressively have fallen off during the daily shower. Figures 3 and 5 show the lesions are weeping less, flattening out, and their diameter are beginning to shrink.
You can view these graphic photos on the Cannabis Science website www.cannabisscience.com and click the button “View Images of 3rd Self-Medicated Patient & His Apparent Success”. You can read more news on this 3rd patient as well on the Cannabis Science website www.cannabisscience.com and click on the breaking news button where you will find all the cancer related and updated patient news.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane, 1-561-234-6929
Investor Relations Management
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com
